ClinicalTrials.gg
CompletedNCT00108758Updated Jan 12, 2017

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

A Phase 2 interventional study of activated recombinant human factor VII in Congenital Bleeding Disorder, Haemophilia A With Inhibitors and Haemophilia B With Inhibitors, sponsored by Novo Nordisk A/S. Completed at 37 sites in 12 countries. Open to male participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
2 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.

Enrollment
11th of 19
23 · median 24
Started
2004
the only one that year
Phase 2
3 of 20
none open now
Registered
1st of 20
by date
Lead sponsor
11 of 20
Novo Nordisk A/S

Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2004, is one of 3 in phase 2, and was the 1st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 2 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing recombinant FVIIa in Hemophilia A, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA).

The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.

03

Conditions studied

  • Congenital Bleeding Disorder
  • Haemophilia A With Inhibitors
  • Haemophilia B With Inhibitors
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of congenital haemophilia A or B with inhibitors development against FVIII or FIX, respectively

Exclusion criteria

Exclusion Criteria:

  • Prophylactic administration of any haemostatic drug within 3 last months prior to entering the trial.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)
06

What researchers measure

Primary outcomes

  1. Reduction of bleeds

    Time frame: During 3 months treatment period as compared to 3 months observation period

Secondary outcomes

  1. Efficacy variables

07

Study locations

37 sites
  • Novo Nordisk Investigational Site
    Berkeley, California 94704, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90027, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60612, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46260, United States
  • Novo Nordisk Investigational Site
    Iowa City, Iowa 52242, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70112-2699, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02115, United States
  • Novo Nordisk Investigational Site
    Detroit, Michigan 48201, United States
  • Novo Nordisk Investigational Site
    Newark, New Jersey 07112, United States
  • Novo Nordisk Investigational Site
    New Hyde Park, New York 11042, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19134-1095, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030, United States
  • Novo Nordisk Investigational Site
    Ciudad Autónoma de Bs. As., C1425ASU, Argentina
  • Novo Nordisk Investigational Site
    Campinas, Sao Paulo 13081970, Brazil
  • Novo Nordisk Investigational Site
    Belo Horizonte, 10130-110, Brazil
  • Novo Nordisk Investigational Site
    Recife, 52011-000, Brazil
  • Novo Nordisk Investigational Site
    Ribeirao Preto, 14051-140, Brazil
  • Novo Nordisk Investigational Site
    Rio de Janeiro, 20211-030, Brazil
  • Novo Nordisk Investigational Site
    Sofia, 1756, Bulgaria
  • Novo Nordisk Investigational Site
    Kremlin-Bicêtre, 94270, France
  • Novo Nordisk Investigational Site
    Lille, 59037, France
  • Novo Nordisk Investigational Site
    Paris, 75015, France
  • Novo Nordisk Investigational Site
    Manila, Philippines
  • Novo Nordisk Investigational Site
    Gdansk, 80-952, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20-954, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 00-576, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 00-791, Poland
  • Novo Nordisk Investigational Site
    Timisoara, Timis 300011, Romania
  • Novo Nordisk Investigational Site
    Bucharest, 022328, Romania
  • Novo Nordisk Investigational Site
    Moscow, 105077, Russian Federation
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 2193, South Africa
  • Novo Nordisk Investigational Site
    Madrid, 28046, Spain
  • Novo Nordisk Investigational Site
    Santander, 39008, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41013, Spain
  • Novo Nordisk Investigational Site
    Bornova-IZMIR, 35100, Turkey
  • Novo Nordisk Investigational Site
    Capa-ISTANBUL, 35100, Turkey
08

References and documents

Publications

  • Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007 Sep;5(9):1904-13. doi: 10.1111/j.1538-7836.2007.02663.x. PubMed 17723130 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Nov 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2005
First posted
Apr 19, 2005
Start
Mar 2004
Primary completionActual
Nov 2005
CompletionActual
Nov 2005
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00108758
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 19, 2005
Start date
Mar 2004
Primary completion
Nov 2005
Completion
Nov 2005
Last update
Jan 12, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion